BioSpace News Archive

Selecta Biosciences, Inc. (NASDAQ: SELB, “Selecta”), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced preclinical data that validate the ImmTOR platform’s potential to enhance the efficacy, safety and durability of adeno-associated viral (AAV) vector gene therapies.

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that it will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. Presentation Details The presentation will be available for on-demand listening beginning Monday, January 11, 2021, at 6:0

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 2:50 p.m. ET. A webcast of the event will be available in the “Events” section of the Lexicon website at www.lexpharma.com . An archived version of the webcast will be available on the website for two week

ReWalk Robotics Ltd. announced that it has repaid in full the outstanding balance on its credit line from Kreos Capital V Limited.

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, is pleased to announce the appointment of Manuel Zafra as the new Managing Director for Canada.

AbbVie (NYSE: ABBV) will participate in the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 . Members of AbbVie’s executive leadership team will present virtually at 3:30 p.m. Central time , including Richard A. Gonzalez , chairman of the board and chief executive officer, Michael Severino , M.D

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) accepted priority review for its New Drug Application (NDA) for mirabegron for oral suspension and its supplemental New Drug Application (sNDA) for Myrbetriq®

New model for instrument and equipment procurement offers customers subscription-based access to technology, and associated consumables, services and support

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler , President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect 2021 C

Omega Therapeutics, Inc. (“Omega”), a development-stage biotechnology company pioneering the field of Epigenomic Programming™ to precisely regulate and control the human genome to treat and cure disease, today announced that Mahesh Karande , President and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Heal